Search

Learn about the latest advances in lung cancer treatment at MSK.

… Friday, November 15, 2024 Lung cancer is the second-most common cancer and remains the leading cause of cancer death in the United States. But a variety of new treatments, many of them developed or tested at Memorial Sloan Kettering Cancer Center (MSK), are helping to bring down the number of deaths.

Conozca los últimos avances en el tratamiento contra el cáncer pulmonar en MSK.

… Friday, November 15, 2024 El cáncer pulmonar es el segundo cáncer más común y sigue siendo la principal causa de muerte por cáncer en los Estados Unidos. Sin embargo, una variedad de nuevos tratamientos, muchos de ellos desarrollados o probados en el Memorial Sloan Kettering Cancer Center (MSK), están

To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.

… Saturday, January 1, 2011 Summary To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center. The goal of the new

Thanks to pioneering work done at MSK, a powerful new form of radiation therapy is changing the treatment of advanced cancers.

… Thursday, September 11, 2025 A high-intensity radiation beam that penetrates the body to burn away tumors has been a standard weapon against cancer for more than a century. Over the years, radiation therapy has improved dramatically, but its effectiveness against cancers in multiple places can be limited

Positive results from a clinical trial published in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab (Yervoy™) and nivolumab (Opdivo™), produced significantly better outcomes than ipilimumab alone in patients with advanced melanoma. A second piece in the same issue from MSK details a dramatic response occurring after a single dose of the combination therapy.

… Monday, April 20, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are reporting exciting results in the field of cancer immunology. Positive results from a clinical trial published today in The New England Journal of Medicine show that the combination of the immunotherapy drugs ipilimumab

Diane Reidy-Lagunes sits down with Mary Elizabeth Williams to discuss what it was like being part of a phase 1 clinical trial, how clear communication can affect health outcomes, how guilt often accompanies survival, and what not to say to a cancer patient.

… Monday, November 29, 2021 When Mary Elizabeth Williams was diagnosed with stage 4 melanoma, she says: “My identity and my relationship with my mortality changed. That was the beginning of my new life.” Her decision to publicly disclose her diagnosis soon after receiving it was easy, she says. “I went

Data from 25,000 patients is helping scientists answer this and many other important questions.

… Thursday, February 3, 2022 Several years ago, in a lab meeting, one of Nikolaus Schultz’s postdoctoral fellows posed a question: “Do you think it’s possible to predict, based on the genomic profile of an individual tumor, which organs it might metastasize to?” And just like that, a research project was

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that Selwyn M. Vickers, MD, FACS, President and Chief Executive Officer of MSK, and Andrea Schietinger, PhD, Associate Member of the Immunology Program at the Sloan Kettering Institute will be honored at the 2023 American Association for Cancer Research (AACR) Annual Meeting for their significant contributions to cancer research and care.

… Friday, April 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce that Selwyn M. Vickers, MD, FACS , President and Chief Executive Officer of MSK, and Andrea Schietinger, PhD , Associate Member of the Immunology Program at the Sloan Kettering Institute will be honored at the

Learn how blood tests called liquid biopsies may be used to find, diagnose, and treat cancer anywhere in the body.

… Monday, September 15, 2025 A blood test to find cancer even before it shows any symptoms is the dream of cancer doctors everywhere.   Researchers at Memorial Sloan Kettering Cancer Center (MSK) are among those hard at work on developing a test that can accurately pick up signs of a tumor anywhere in

Memorial Sloan Kettering President and CEO Craig Thompson reflects on the life and career of cancer research pioneer Janet Rowley.

… Friday, December 20, 2013 Summary Memorial Sloan Kettering President and CEO Craig Thompson reflects on the life and career of cancer research pioneer Janet Rowley. I learned with great sadness earlier this week of the death of Janet Davison Rowley. A few years ago, the New York Times called Dr. Rowley